Grassley probes journals for ghostwriting info

Share this article:
Sen. Chuck Grassley (R-IA) asked eight journals to provide information about their medical ghostwriting practices and policies, in an effort to “shed light on the role companies may play in the dissemination of information about their products through medical literature.”

Grassley's most recent probe into ghost writing practices took the form of a letter sent to the American Journal of Medicine, the Annals of Internal Medicine, the Annual Review of Medicine, the New England Journal of Medicine, JAMA and others.

The letter, dated July 2, requested that publishers detail their editorial policies with respect to third parties involved in the “development and/or writing of a journal article,” and any actions taken against an author for failing to disclose this information. Grassley asked that all of the journals respond by July 22.

“Public dollars and the public trust are at stake in the practice of medicine, and the information that is shared in these journals can influence decisions made by doctors and their patients,” said Grassley in a release. “Transparency can do a lot of good in building confidence that there's nothing to hide, and that applies to how expert opinion is presented in public forums like these journals provide.”

In the past, Grassley has requested ghostwriting-related information from Wyeth and Merck over allegations that both companies signed authors on to published articles and clinical research inappropriately.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...